A major feature of the disease is a condition known as insulin resistance. Insulin is a hormone that moves glucose (sugar), from the bloodstream into the body’s cells where it is used for energy. For a variety of reasons that are not fully understood, the body’s tissues don’t respond adequately to insulin and glucose then becomes elevated in the bloodstream.
If the amount of insulin available is insufficient, or if cells respond poorly to the effects of insulin (insulin insensitivity or insulin resistance), or if the insulin itself is defective, then glucose will not be absorbed properly by the body cells that require it, and it will not be stored appropriately in the liver and muscles. The net effect is persistently high levels of blood glucose, poor protein synthesis, and other metabolic derangements, such as acidosis.
First, the health of your gut is critical to your overall health. This is because your gut is home of trillions of microbes called the gut microbiome. These microbes work in symbiotic and antagonistic relationships within your body. A 2017 study using multiple therapies to manipulate the gut microbiome composition, found they could impact the individual’s health more rapidly. This study also found manipulating the gut microbiome as an effective way to avoid insulin resistance and therefore prevent diabetes.
In 2003, ephedrine -- also known as ma huang -- became the first herbal stimulant ever banned by the FDA. It was a popular component of over-the-counter weight loss drugs. Ephedrine had some benefits, but it could cause far more harm, especially in high doses: insomnia (difficulty falling and staying asleep), high blood pressure, glaucoma, and urinary retention. This herbal supplement has also been associated with numerous cases of stroke.
Founded in 1999, San Diego-based ViaCyte has raised a total of $201.5 million in funding, with major investments from Johnson & Johnson and Bain Capital. ViaCyte is addressing diabetes by developing a technology based on converting stem cells into pancreatic tissue that can produce insulin, and implanting the new tissue into patients inside an immunoprotective device for continuous insulin production.
He asked and then demanded that the 200 or so chairs in the middle of the auditorium be rearranged. This required summoning the fire marshal (as the aisle was a matter of code) who insisted that no changes could be made. Brand held his ground. Event planners gathered around him trying to talk him down. Even if it weren’t for the fire code, moving the chairs at this point would have to be done by union workers and would take time. The audience was waiting outside baking in the sun, Hoess, Wanderlust’s CEO, reminded Brand. But he was insistent. I sensed he was willing to threaten to not go on at all when the organizers finally broke down and agreed to move the chairs.